A study in The BMJ revealed that 60% of U.S. panel members and task force members on the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders (DSM), fifth edition, text revision had undisclosed industry funding, to the tune of $14.2 million. “Our study was not designed (nor could it be) to determine if these financial ties affected decision making,” the authors wrote.
While apparent renewed interest in the development of novel antipsychotics may be a reason to be optimistic, that alone is not enough to improve outcomes for people with schizophrenia, cautioned an editorial in The Lancet discussing the new era of schizophrenia treatments in the pipeline.
More and more states are looking to protect kids from the mental health harms of social media. (Politico)
The antipsychotic drugs quetiapine and haloperidol were linked with an increased risk of ventricular arrhythmias and sudden cardiac death stemming from drug-induced QT prolongation. (HeartRhythm)
Depression symptom increases were tied with a subsequent rise in body weight among people with overweight or obesity. (PLOS One)
The FDA approved BrainSee, a software platform that combines MRI and cognitive assessments to predict likelihood of progression to Alzheimer’s dementia, maker Darmiyan announced.
FOMO — aka, the fear of missing out — and boredom proneness played an important role in the relationship between symptoms of obsessive compulsive disorder and problematic smartphone use. (Current Psychology)
After a systematic evaluation, the best machine learning algorithm only achieved a diagnostic classification accuracy of 62% for identifying the neural signature of major depressive disorder. (JAMA Psychiatry)
Anavex Life Sciences announced the start of a phase II clinical trial of its dual SIGMAR1 receptor agonist and M1 positive allosteric modulator ANAVEX3-71 for schizophrenia.
![author['full_name']](https://clf1.medpagetoday.com/media/images/author/kristenMonaco_188.jpg)
Please enable JavaScript to view the